Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al
The ability of benfotiamine to inhibit three major pathways (the hexosamine pathway, the AGE formation pathway, and the diacylglycerol (DAG)-PKC pathway) simultaneously might be clinically useful in preventing the development and progression of diabetic complications
Covalent aggregates form when monomeric proteins become chemically crosslinked, e.g., though disulfide bonds
Temperature changes, chills, hair shedding, sulfur burps, and low mood appear more often in user reports than in trial tables
Contraindications include active malignancy, uncontrolled diabetes, pregnancy, or history of certain cancers